ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2020
Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Influenza and Human Papillomavirus Vaccine Utilisation in Vulnerable Urban Youth in Edmonton, Alberta, Canada.The International journal of health planning and management · 2026Article
- Influenza vaccine strain selection with an AI-based evolutionary and antigenicity model.Nature medicine · 2025Article
- Interim estimates of vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2) during a delayed influenza season, Canada, 2024/25.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines.Human vaccines & immunotherapeutics · 2024Review
- Article
- 2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN).Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Does the Australian influenza season predict the Canadian influenza season? A qualitative comparison of seasons, 2014-2020.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2023Article
- 2019-2020 H1N1 clade A5a.1 viruses have better in vitro fitness compared with the co-circulating A5a.2 clade.Scientific reports · 2023Article
- Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Article
- Respiratory viruses: New frontiers-a Keystone Symposia report.Annals of the New York Academy of Sciences · 2023Article
- 2019-20 H1N1 clade A5a.1 viruses have betterbioRxiv : the preprint server for biology · 2023Article
- Immune interference in effectiveness of influenza and COVID-19 vaccination.Frontiers in immunology · 2023Review
- The evolutionary footprint of influenza A subtype H3N2 strains in Bangladesh: implication of vaccine strain selection.Scientific reports · 2022Article
- Roles for Pathogen Interference in Influenza Vaccination, with Implications to Vaccine Effectiveness (VE) and Attribution of Influenza Deaths.Infectious disease reports · 2022Review
- Article
- Article
- National FluWatch mid-season report, 2021-2022: Sporadic influenza activity returns.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2022Article
- Influenza Vaccine Effectiveness for Prevention of Severe Influenza-Associated Illness Among Adults in the United States, 2019-2020: A Test-Negative Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- HIV self-testing in Ottawa, Canada used by persons at risk for HIV: The GetaKit study.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interim results from Canada's Sentinel Practitioner Surveillance Network show that during a season characterised by early co-circulation of influenza A and B viruses, the 2019/20 influenza vaccine has provided substantial protection against medically-attended influenza illness. Adjusted VE overall was 58% (95% confidence interval (CI): 47 to 66): 44% (95% CI: 26 to 58) for A(H1N1)pdm09, 62% (95% CI: 37 to 77) for A(H3N2) and 69% (95% CI: 57 to 77) for influenza B viruses, predominantly B/Victoria lineage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.